Pharmaxis drug cops red flag from US regulator

AUSTRALIAN biotechnology company Pharmaxis has confirmed the US Food and Drug Administration has rejected its bid to market the cystic fibrosis drug Bronchitol in the US.

The FDA recommended that Pharmaxis conduct an additional clinical trial to obtain approval for the drug.

"The submitted data do not provide a favourable benefit-risk balance to support the use of inhaled mannitol in patients with cystic fibrosis six years of age and older," the FDA said in a letter to Pharmaxis following its meeting on Monday.

"The determination of efficacy based on the two clinical trials are not adequate because of the treatment-related frequent early dropouts in trial 301 for which the primary statistical analyses did not account and the lack of statistical significance in trial 302 for the primary endpoint."

Shares in Pharmaxis, which were in a trading halt ahead of the announcement, rose by up to 6 per cent before falling following the lifting of the trading halt. It was trading 2 per cent lower at 49 cents about 1.20pm.

Read more at Brisbanetimes.com.au
 



BREAKING: People evacuated from Lismore Base Hospital

BREAKING: People evacuated from Lismore Base Hospital

A number of people have been evacuated this afternoon

Investigation continues after girl's tragic death

Investigation continues after girl's tragic death

Car is being mechanically examined as police wait on test results

Hopes new development won't stifle music scene

premium_icon Hopes new development won't stifle music scene

Venue hopes proposed development won't lead to noise complaints

Local Partners